Hoth Therapeutics, Inc.
3.4M
$7.26M
-1.10
$-0.90
No price alerts set. Add an alert to get notified!
-1.10
2.22
$-0.90
-202.73%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ASBP
Aspire Biopharma Holdings, Inc.
|
$1.01 | -1.94% | -0.06 | $3.50M | -0.22 |
|
BCTX
BriaCell Therapeutics Corp.
|
$4.14 | -1.19% | -0.27 | $7.80M | 0.00 |
|
CRIS
Curis, Inc.
|
$0.53 | -2.61% | -9.25 | $7.02M | 0.30 |
|
DARE
Daré Bioscience, Inc.
|
$1.90 | 4.40% | -2.06 | $18.09M | 934.35 |
|
ENTO
Entero Therapeutics, Inc.
|
$2.85 | -5.00% | -0.26 | $13.58M | 0.01 |
|
FBLG
FibroBiologics, Inc. Common Stock
|
$1.33 | 0.76% | -0.16 | $2.79M | 0.39 |
|
LEXX
Lexaria Bioscience Corp.
|
$0.87 | 11.04% | -1.72 | $16.74M | 0.02 |
|
PALI
Palisade Bio, Inc.
|
$1.88 | 7.43% | -6.24 | $311.86M | 0.00 |
|
PCSA
Processa Pharmaceuticals, Inc.
|
$2.60 | 3.09% | -0.49 | $5.90M | 0.00 |
|
PULM
Pulmatrix, Inc.
|
$1.32 | 2.33% | -0.93 | $4.82M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$2.12
$0.50
$0.00
0.00%
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
